GSK's herpes zoster vax candidate flies into Phase III; Sanofi Pasteur will begin shipping Fluzone;

> Researchers saw delayed tumor growth in mice given both an immune system booster and chemical counter to cancer's secretions. Story

> Sanofi Pasteur will begin shipping the Fluzone vaccine following an FDA licensure of the 2012-2013 formulation. Release

> The MVA85A tuberculosis vaccine is undergoing two Phase IIb proof-of-concept clinical studies. News

> Rotary Ghana and Rotary International have funded a vaccine cold room for the Greater Accra Regional Health Directorate. Item

> Chembio signed a $480,000 agreement with a Center for Disease Control contractor for an influenza immunity test. Article

> CSIRO, contracted by PATH, will produce antibodies for the development of new vaccines against rotavirus. More

And Finally... GlaxoSmithKline's ($GSK) herpes zoster vaccine candidate has commenced a global, randomized placebo-controlled Phase III clinical trial for the prevention of shingles in immunocompromised patients. Release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.